The future of animal models of invasive aspergillosis

References

• Andriole VT, Miniter P, George D, et al. Animal models: Usefulness for studies of fungal pathogenesis and drug efficacy in aspergillosis. Clin Infect Dis 1992; 14(Suppl 1)S134–S138
   Google Scholar
• Patterson TF, Miniter P, Patterson JE, et al. Aspergillus antigen detection in the diagnosis of invasive aspergilosis. J Infect Dis 1995; 171: 1553–1558
   Google Scholar
• Graybill JR. The role of murine models in the development of antifungal therapy for systemic mycoses. Drug Resist Update 2000; 3: 364–383
   Google Scholar
• Najvar LK, Cacciapuoti A, Hernandez S, et al. Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories. Antimicrob Agents Chemother 2004; 48: 758–764
   PubMed Web of Science ®Google Scholar
• Patterson T, Miniter P, Ryan J, Andriole V. Effect of Immunosuppression and amphotericin B on aspergillus antigenemia in an experimental model. J Infect Dis 1988; 158: 415–422
   PubMed Web of Science ®Google Scholar
• Sabetta J, Miniter P, Andriole V. The diagnosis of invasive aspergillosis by an enzyme-linked immunosorbent assay for circulating antigen. J Infec Dis 1985; 152: 946–953
   PubMed Web of Science ®Google Scholar
• Patterson TF, George D, Ingersoll R, et al. Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis. Antimicrob Agents Chemother 1991; 35: 1985–1988
   PubMed Web of Science ®Google Scholar
• Patterson TF, Fothergill AW, Rinaldi MG. Efficacy of itraconazole solution in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother 1993; 37: 2307–2310
   PubMed Web of Science ®Google Scholar
• Patterson TF, George D, Miniter P, Andriole VT. Saperconazole therapy in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother 1992; 36: 2681–2685
   PubMed Web of Science ®Google Scholar
• Patterson TF, Miniter P, Dijkstra J, et al. Treatment of experimental invasive aspergillosis with novel amphotericin B/cholestrol-sulfate complexes. J Infect Dis 1989; 159: 717–721
   PubMed Web of Science ®Google Scholar
• Kirkpatrick WR, McAtee RK, Fothergill AW, et al. Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother 2000; 44: 2865–2868
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003; 187: 1834–1843
   PubMed Web of Science ®Google Scholar
• Petraitiene R, Petraitis V, Groll AH, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: Pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002; 46: 12–23
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Benjamin DK, Jr, Trasi SA, et al. Value of an inhalational model of invasive aspergillosis. Med Mycol 2004; 42: 417–425
   PubMed Web of Science ®Google Scholar
• Dixon DM, Polak A, Walsh TJ. Fungus dose-dependent primary pulmonary aspergillosis in immunosuppressed mice. Infect Immun 1989; 57: 1452–1456
   PubMed Web of Science ®Google Scholar
• Allende MC, Lee JW, Francis P, et al. Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrob Agents Chemother 1994; 38: 518–522
   PubMedGoogle Scholar
• Warn PA, Morrissey G, Morrissey J, Denning DW. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. J Antimicrob Chemother 2003; 51: 913–919
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Perfect JR. Newer antifungal therapy for emerging fungal pathogens. Int J Infect Dis 2003; 7: 5–20
   PubMedGoogle Scholar
• Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000; 79: 250–260
   PubMed Web of Science ®Google Scholar
• Wald A, Leisenring W, van Burik J-A, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459–1466
   PubMed Web of Science ®Google Scholar
• Marty FM, Lee SJ, Fahey MM, et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003; 102: 2768–2776
   PubMed Web of Science ®Google Scholar
• Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190: 641–649
   PubMed Web of Science ®Google Scholar
• Graybill JR, Kaster S, Drutz D. Treatment of experimental murine aspergillosis with BAY n7133. J Infec Dis 1983; 148: 898–906
   PubMedGoogle Scholar
• Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002; 46: 2564–2568
   PubMed Web of Science ®Google Scholar
• Bowman JC, Abruzzo GK, Anderson JW, et al. Quantitative OCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: Demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 2001; 45: 3474–3481
   PubMed Web of Science ®Google Scholar
• Loeffler J, Kloepfer K, Hebart H, et al. Polymerase chain reaction detection of aspergillus DNA in experimental models of invasive aspergillosis. J Infect Dis 2002; 185: 1203–1206
   PubMed Web of Science ®Google Scholar
• Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39: 199–205
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Garrett K, Feuerstein E, et al. Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy. Antimicrob Agents Chemother 1995; 39: 1065–1069
   PubMed Web of Science ®Google Scholar
• Sheppard DC, Rieg G, Chiang LY, et al. Novel inhalational murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2004; 48: 1908–1911
   PubMed Web of Science ®Google Scholar
• McMurray DN. Disease model: pulmonary tuberculosis. Trends Mol Med 2001; 7: 135–137
   PubMed Web of Science ®Google Scholar
• Kirkpatrick, WR, Coco, BJ, Patterson, TF. A new animal model of invasive pulmonary aspergillosis (IPA) using large scale inhalational challenge. In:. Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, WashingtonDC, 30 October – 2 November; 2004.
   Google Scholar
• Zaas, A, Steinbach, W, Burch, L, Perfect, J, Schwartz, D. Susceptibility to Aspergillus fumigatus: Role of Host Genetic Background. In:. Abstracts of the 7th Annual European Conference on Fungal Genetics, Copenhagen, Denmark; 2004.
   Google Scholar